Should I Buy OABI? OABI 2026 Analysis

Should You Buy OmniAb Inc (OABI) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Sell

Latest Price

1.700

1 Day change

3.03%

52 Week Range

4.020

Analysis Updated At

2026/02/05

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now: price action and pattern-based projection both lean bearish (expected -4.3% next week, -9.19% next month).
Oversold RSI can trigger a short bounce, but momentum (MACD) is still deteriorating and there’s no confirmed reversal signal.
No near-term catalysts (no news) to change the narrative, while fundamentals show shrinking revenue and deeply negative margins.
Trading flows: hedge funds/insiders neutral; no notable politician/congress activity to validate a bullish thesis.

Intellectia Proprietary Trading Signals

AI Stock Picker: no signal on given stock today.
SwingMax: No signal on given stock recently.

Technical Analysis

Trend/Momentum: MACD histogram at -0.0298 (below zero) and negatively expanding → bearish momentum is strengthening.
Oversold: RSI(6) = 14.446 → extremely oversold; bounce risk is elevated but does not equal a trend reversal.
Moving averages: converging MAs suggest a potential inflection zone, but current momentum still favors downside.
Levels: Current price 1.655 is below S1 (1.681) and closer to S2 (1.581) → weak structure; overhead resistance sits at Pivot 1.843 then R1 2.006.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Positioning: Put/Call open interest ratio = 0.02 (calls dominate OI) → options positioning is heavily call-skewed/bullish, but can also reflect speculative upside chasing in a distressed name.
Activity: today’s options volume is 0 (and volume vs 30D avg is 0) → sentiment signal is weak in real-time despite the call-heavy open interest.
Volatility: 30D IV ~211% (IV percentile 74.5) vs historical vol ~38% → options are pricing very large moves; market is demanding a high premium for exposure.

Technical Summary

Sell

Buy

Positive Catalysts

becomes more plausible.

Neutral/Negative Catalysts

- Bearish momentum is accelerating (MACD histogram expanding negatively) while price sits below nearby support (S1).
- No news in the past week → no clear event-driven catalyst to reverse sentiment.
- Pattern-based outlook for similar setups points to continued weakness over 1W/1M horizons.
- Macro tape is risk-off today (S&P 500 -1.21%), which can pressure small/speculative names.

Financial Performance

Latest quarter: 2025/Q3.
Revenue: 2.239M, down -46.33% YoY → sharp top-line contraction.
Net income: -16.525M (loss), up 0.93% YoY → still deeply unprofitable with only marginal improvement.
EPS: -0.14, down -12.50% YoY → per-share performance worsened.
Gross margin: -45.47% (down -145.47% YoY) → indicates severe margin pressure/negative gross profitability, a major fundamental headwind.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target change data was provided, so a Wall Street consensus trend cannot be confirmed from this dataset.
Practical pro/con view from available info: Pros—possible oversold bounce and call-skewed OI. Cons—rapid revenue decline, negative gross margin, ongoing losses, and weakening technical momentum.

6 Analyst Rating

Wall Street analysts forecast OABI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OABI is 6.8 USD with a low forecast of 3 USD and a high forecast of 11 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

6 Buy

0 Hold

0 Sell

Strong Buy

Current: 1.650

Low

Averages

6.8

High

Current: 1.650

Low

Averages

6.8

High

Craig-Hallum

Buy

downgrade

$10 -> $7

AI Analysis

2025-11-05

Reason

Craig-Hallum

Price Target

$10 -> $7

AI Analysis

2025-11-05

downgrade

Buy

Reason

Craig-Hallum lowered the firm's price target on OmniAb to $7 from $10 and keeps a Buy rating on the shares. The firm notes the company reported several positive developments this quarter, driven by strong business momentum and a growing network of 104 active partners. Additionally, Craig-Hallum believes that the launch of OmniUltra, following last quarter's introduction of the xPloration Partner Access Program, should facilitate the development of new classes of biologically derived peptide therapeutics and this innovation will drive further partnerships.

RBC Capital

Conor McNamara

Buy

Maintains

$7 → $4

2025-03-27

Reason

RBC Capital

Conor McNamara

Price Target

$7 → $4

2025-03-27

Maintains

Buy

Reason

RBC Capital lowered the firm's price target on OmniAb to $4 from $7 and keeps an Outperform rating on the shares. The company provided lower than expected FY25 revenue guidance, though the outlook is prudent and de-risks lumpy contributions due to its partner's program progression, the analyst tells investors in a research note. RBC adds that its takeaways from OmniAb Q4 include continued program growth with healthy end markets and its view that FY25 revenue guide is achievable with lower cash spend.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for OABI

Unlock Now

OABI Should I Buy

OABI Should I Buy

Should You Buy OmniAb Inc (OABI) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch